NCT05606237

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

Recruiting now NA Last updated 28 January 2026

What this trial tests

NA trial testing Low-level Red Light Therapy Device in Myopia in 90 participants. Currently enrolling.

Timeline

14 July 2023

Primary endpoint
14 January 2027

14 January 2027

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	14 July 2023
Primary completion	14 January 2027
Estimated completion	14 January 2027
Sites	1 location across United States

Drugs / interventions tested

• Low-level Red Light Therapy Device

Conditions studied

• Myopia — all drugs for Myopia →

Sponsor

University of California, San Francisco

Who can join

Adults 8 to 13, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Photobiomodulation Therapy: The Dawn of Myopia Control.
   Gettinger K, Huang Y, Tsubota K, Negishi K, et al · · 2026 · PMID 41892317 · DOI 10.3390/cells15060526